Role of β-microseminoprotein from prostate cancer initiation to recurrence: A mini-review

Table 2 Relative expression of PCA3 and PSA genes in cells captured from urine of patients undergone various treatments

Treatment type	Relative PCA3 gene expression	Relative PSA geneexpression	PCA3score1
RP and RT	0	0	0
RP and RT	3.91	6.45	0.61
RP and RT	0	0	0
RP and RT	0	0	0
RP and RT	5.03	4.67	1.08
RT	0	0	0
RT	0	0	0
RT	4.76	0	-
RT	4.24	4.23	1
RT	4.94	1.86	2.66
ADT and RT	0	0	0
ADT and RT	0	0	0
ADT and RT	0	3.72	-
ADT and RT	0	0	0
ADT and RT	0	0	0
ADT and RT	0	0	0
RP + RT and ADT	0	7.39	0
ADT	0	0	0
ADT	4.39	5.47	0.8
ADT	0	0	0
ADT	0	0	0
ADT	0	0	0
ADT	0	0	0
ADT	0	0	0
RP and NFT	2.23	0	-
RP and NFT	7.97	2.83	2.82
RP and NFT	3.04	3.22	0.94
RP and NFT	0.39	0.34	1.15
RP and NFT	6.56	3.53	1.86
RP and NFT	6.05	4.67	1.3
RP and NFT	0	0	0
RP and NFT	2.33	1.53	1.52
AS	6.02	7.2	0.84
AS	2.83	2.14	1.32
AS	5.42	Not available	-
AS	3.18	2.93	1.09
AS	6.53	8.13	0.8

¹PCA3 score is the ratio between relative PCA3 and relative PSA gene expression. PSA: Prostate specific antigen; PCA3: Prostate cancer gene 3; RP: Radical prostatectomy; RT: Radiation therapy; NFT: No further treatment; AS: Active Surveillance; ADT: Androgen deprivation therapy.